Core Viewpoint - NeOnc Technologies Holdings, Inc. has announced promising data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, a novel oral bio-conjugated therapy for central nervous system cancers, indicating early signs of clinical efficacy and establishing a Recommended Phase 2 Dose (RP2D) of 610 mg [1][2][5]. Group 1: Clinical Trial Progress - The Phase 1 dose-escalation portion of the NEO212-01 clinical trial reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg) after a second Dose-Limiting Toxicity, leading to the establishment of the RP2D at 610 mg [2]. - The Phase 2a metastasis cohort will start with a dose of 400 mg [2]. - Early signs of clinical efficacy were observed, including indications of lasting disease control in heavily pretreated patients with recurrent glioblastoma and brain metastases [3][4]. Group 2: Therapeutic Potential - The emergence of measurable anti-tumor activity in Phase 1 supports the therapeutic potential of NEO212 and the transition into Phase 2 [4]. - NEO212 is designed to overcome MGMT-mediated resistance, a key limitation of the current standard of care, temozolomide (TMZ) [9][10]. - The bio-conjugated oral formulation of TMZ aims to enhance therapeutic performance while maintaining the practicality of oral administration [8]. Group 3: Regulatory and Development Plans - NeOnc plans to request a Type B (End-of-Phase 1) FDA meeting to discuss safety, pharmacokinetics, preliminary efficacy, and potential Accelerated Approval pathways [6]. - The company is preparing for a pivotal registrational Phase 2 study, contingent on FDA feedback and approval [8]. - The determination of the RP2D at 610 mg is seen as a significant achievement, allowing NeOnc to proceed with efficacy studies for patients in need of new oral therapies [11].